IMARC Group, a leading market research company, has recently releases report titled “Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global antihyperlipidemic drugs market size, growth, share, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Industry Overview of Antihyperlipidemic Drugs

Antihyperlipidemic drugs are medications designed to lower levels of lipids, such as cholesterol and triglycerides, in the blood. They work through various mechanisms to reduce lipid synthesis, increase lipid excretion, or improve lipid metabolism. They include statins, fibrates, and niacin, among others. Amongst these, statins are particularly well-known for their effectiveness in reducing levels of low-density lipoprotein (LDL) cholesterol. Antihyperlipidemic drug administration can help manage lipid levels and reduce the risk of cardiovascular events.

How Big Is the Antihyperlipidemic Drugs Market?

The global antihyperlipidemic drugs market size reached US$ 12.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

Request Sample Copy of This Report: https://www.imarcgroup.com/antihyperlipidemic-drugs-market/requestsample

What are the growth prospects and trends in the antihyperlipidemic drugs industry?

The surging prevalence of various chronic medical conditions, such as cardiovascular diseases and obesity, and the increasing elderly population that are more susceptible to these disorders represent one of the primary factors driving the demand for antihyperlipidemic drugs around the world.

Moreover, initiatives undertaken by government and non governmental programs to advocate for cholesterol management are favoring the growth of the market. In addition, the rising inclination towards antihyperlipidemic drugs to improve the low levels of high density lipoprotein (HDL) cholesterol and reduce the high levels of low density lipoprotein (LDL) cholesterol and triglycerides is contributing to the market growth.

Apart from this, the growing occurrence of hyperlipidemia on account of a sedentary lifestyle and the high consumption of fatty foods and nicotine addiction is influencing the market positively.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163